B cell infiltration in systemic sclerosis-associated interstitial lung disease

Arthritis and Rheumatism

Volumn 56, Issue 9, 2007, Pages 3167-3168

  Lafyatis, Robert ^a   O'Hara, Carl ^a   Feghali Bostwick, Carol A ^b   Matteson, Eric ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG PARENCHYMA; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MEMORY CELL; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN DISEASE; STAINING; SYSTEMIC SCLEROSIS; SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE;

B-LYMPHOCYTES; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC;

EID: 34848833579     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22847     Document Type: Article

References (12)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
3. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-27.
4. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20: "what do B-cells do?" Clin Immunol 2005;117:207-13.
5. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006;66:1933-48.
6. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27.
7. Hasegawa M, Fujimoto M, Takehara K, Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005;39:1-7.
8. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 2003;100:12319-24.
9. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759-67.
10. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
11. Atkins SR, Turesson C, Myers JL, Tazelaar HD, Ryu JH, Matteson EL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 2006;54:635-41.
12. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006;176:5735-9.